Synthesis and evaluation of novel podophyllotoxin derivatives as potential antitumor agents
摘要:
Cancer multidrug resistance (MDR) is a common cause of treatment failure in cancer patients. Increased expression of permeability glycoprotein (P-gp), which is also known as MDR-1, is the main cause of multidrug resistance. Podophyllotoxin derivatives hold great promise in the battle to overcome multidrug resistance, as they can induce cytotoxicity through multiple mechanisms. Here, we synthesized sixteen novel podophyllotoxin derivatives and evaluated their cytotoxicities in human cancer cell lines, HeLa, 1(562 and K562/A02. Some of these compounds were more potent than etoposide, a clinically relevant inhibitor of DNA repair enzymes. In particular, compound 5p exhibited the most potent activity toward drug-resistant K562/A02 cells, as it robustly inhibited tumor cell proliferation and induced apoptosis. Furthermore, preliminary investigation suggested that 5p inhibited the expression of MDR-1 in K562/A02 cells more effectively than etoposide. (C) 2014 Elsevier Masson SAS. All rights reserved.
Cholinergic Agents Structurally Related to Furtrethonium. 2. Synthesis and Antimuscarinic Activity of a Series of N-[5-[(1'-Substituted-acetoxy)methyl]-2-furfuryl]dialkylamines
In the first part of this study, devoted to the discovery of selective antimuscarinic agents, (+/-)- N-[5-[(1'-phenyl-1'-cyclohexylacetoxy)methyl]-2-furfuryl]dimeth yla mine (5a) proved to be at least 20 times more potent in the rat ileum and bladder than in guinea pig atria. Several (+/-)-N- [5-[(1'-substituted-acetoxy)methyl]-2-furfuryl]dialkylamine analogs of 5a were subsequently prepared. This
2-(Pyrazol-5-yl-oxymethyl)-1,2-benzisothiazol-3(2H)-one 1,1-dioxides, pharmaceutical compositions containing them and methods for the treatment of degenerative diseases utilizing them.
Efficient reductive amination of HMF with well dispersed Pd nanoparticles immobilized in a porous MOF/polymer composite
作者:Vikram V. Karve、Daniel T. Sun、Olga Trukhina、Shuliang Yang、Emad Oveisi、Jeremy Luterbacher、Wendy L. Queen
DOI:10.1039/c9gc03140e
日期:——
employed in the reductive amination of HMF under mild conditions. The catalyst shows excellent activity, including a high TON/TOF (h−1) of 604.8/302.4 and ∼94% amine yield, which is maintained over a larger number of reaction cycles (up to 15) when compared to several state-of-the-art materials, such as a commercial Pd/C (3 cycles). It is thought that the origin of the improved catalyst recyclability
[EN] 2-(PYRAZOL-5-YL-OXYMETHYL)-1,2-BENZISOTHIAZOL-3(2H)-ONE 1,1-DIOXIDES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM<br/>[FR] 1,1-DIOXYDES DE 2-(PYRAZOL-5-YL-OXYMETHYL)-1,2-BENZOTHIAZOL-3(2H)-ONE ET COMPOSITIONS PHARMACEUTIQUE LES CONTENANT
申请人:SANOFI
公开号:WO1997010243A1
公开(公告)日:1997-03-20
(EN) 2-(Pyrazol-5-yl-oxymethyl)-1,2-benzisothiazol-3(2H)-one 1,1-dioxides of formula (I), pharmaceutical compositions containing them and methods for the treatment of degenerative diseases utilizing them.(FR) La présente invention concerne des 1,1-dioxydes de 2-(pyrazol-5-yl-oxyméthyl)-1,2-benzothiazol-3(2H)-one représentés par la formule (I). L'invention concerne également des compositions pharmaceutiques les contenant et des procédés de traitement d'affections dégénératives dans lesquels ces compostions pharmaceutiques sont utilisées.